Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NCT05424003 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help prevent weight gain in people who have had a liver transplant due to non-alcoholic fatty liver disease (NAFLD).

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind prevention study

Participants 50 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2024-02 · est. completion 2026-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05424003 ↗

Description as written by the study sponsor.

In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.

Treatments tested

Semaglutide Pen Injector also known as Wegovy Drug

Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
Placebo Drug

Placebo solution injected weekly for 72 weeks

Main thing measured	Change in weight
Sponsor	Virginia Commonwealth University
Conditions studied	NAFLD
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05424003 ↗